Poxel Sumitomo Dainippon\'s experimental type 2 diabetes drug imeglimin meets main goal of Phase III study httpswww.firstwordpharma.comnode1634101Â
Poxel, Sumitomo Dainippon's experimental type 2 diabetes drug imeglimin meets main goal of Phase III study https://www.firstwordpharma.com/node/1634101
More From BioPortfolio on "Poxel, Sumitomo Dainippon's experimental type 2 diabetes drug imeglimin meets main goal of Phase III study https://www.firstwordpharma.com/node/1634101 "